AAN

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
Wednesday, April 3, 2024
Athira Pharma, HGF, AAN, Nervous system, ALS, American Academy, Annual general meeting, American Academy of Neurology, Pharmaceutical industry

BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.

Key Points: 
  • BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting , to be held April 13 – 18, 2024, in Denver, Colorado and online.
  • The presentation will highlight preclinical data supporting the continued development of Athira's pipeline of small molecule candidates targeting the neurotrophic hepatocyte growth factor (HGF) system, including fosgonimeton for Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease.
  • Athira’s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the nervous system.
  • Athira’s drug candidates have distinct properties, which the company believes may be applicable to a broad range of neurodegenerative diseases.

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Neurology, Friends, AAN, Social media, Annual general meeting

CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting , taking place April 13-18, 2024 virtually and in Denver, Colorado.

Key Points: 
  • CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting , taking place April 13-18, 2024 virtually and in Denver, Colorado.
  • Presentation details are as follows:
    The AAN Annual Meeting is the largest gathering of neurologists and neuroscience professionals and offers top-tier education, the latest in scientific discoveries, and an abundance of opportunities to connect with friends and colleagues from around the globe.
  • For more information about Vaxxinity, Inc., visit https://vaxxinity.com/ and follow us on social media @vaxxinity.

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Tuesday, April 9, 2024
Health, Other Science, General Health, Clinical Trials, Research, Science, Pharmaceutical, Hypersensitivity, Anaphylaxis, Angioedema, Brain, Eptinezumab, Virtual Private LAN Service, Headache, Patient, American Academy, Interview, MD, Neurology, Migraine, Lundbeck, Quality of life, AAN, Abstract, Pharmaceutical industry

These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Key Points: 
  • These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
  • “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
  • We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
    VYEPTI is indicated for the preventive treatment of migraine in adults.
  • The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

Retrieved on: 
Thursday, March 21, 2024
Diagnosis, Biomarker, American Academy, Science, AAN, Safety, ABOS, Powder metallurgy

CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the Company will present data from its Phase 1 INTERCEPT-AD study evaluating sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) Annual Meeting in Denver, Colo., and online on Tuesday, April 16.

Key Points: 
  • CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the Company will present data from its Phase 1 INTERCEPT-AD study evaluating sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) Annual Meeting in Denver, Colo., and online on Tuesday, April 16.
  • Acumen’s sabirnetug is the first humanized monoclonal antibody to clinically demonstrate target engagement of AβOs, a soluble and highly toxic form of Aβ that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration.
  • Acumen’s presentation will include deeper insights into the safety, target engagement and biomarker findings from INTERCEPT-AD.
  • “We’re eager to present more extensive findings from our sabirnetug program, which further our understanding of key biomarkers associated with AD and support broader efforts that can aid in diagnosis and treatment of this devastating disease.”
    Acumen is on track to initiate a Phase 2 trial evaluating sabirnetug in the first half of 2024.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Janus, Research, MMN, Myasthenia gravis, Dianthus, GMG, CIDP, Half-life, Form, Patient, Complement component 1s, Magenta, Acetylcholine, American Academy, CMC, G&A, YTE, Drug, AAN, Investment, Therapy, PIPE, Magic, Multifocal motor neuropathy, Annual general meeting, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023, and provided an update on recent business achievements.

Key Points: 
  • DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
  • Initial top-line results from this trial are anticipated to be available in the second half of 2025.
  • Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
  • Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the SEC.

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Microglia, American Academy, American Academy of Neurology, ALSP, AAN, Poster

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.

Key Points: 
  • WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
  • Details of the oral presentation are as follows:
    Title: Interim Results on VGL101 From IGNITE: First Interventional Phase 2 Study in Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
    Details of the poster presentations are as follows:
    Presented by: David S. Lynch, M.D., Ph.D., National Hospital for Neurology & Neurosurgery; University College London Institute of Neurology

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

Cognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Neurology, Medical Devices, Health, Clinical Trials, Cognito, AAN, Disease, American Academy, Therapy, CO, OLE, Annual general meeting, Pharmaceutical industry

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension (OLE) study of Spectris™, a potential disease modifying therapy for the treatment of Alzheimer’s Disease, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, 2024, in Denver, CO.

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension (OLE) study of Spectris™, a potential disease modifying therapy for the treatment of Alzheimer’s Disease, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, 2024, in Denver, CO.
  • The OLE study was a separate 12-month protocol that followed the six-month OVERTURE randomized clinical trial, in which 83% of OVERTURE study participants enrolled.
  • The OLE enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.
  • For more information about the AAN abstract, visit https://www.aan.com/msa/Public/Events/AbstractDetails/55258 .

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Friday, March 8, 2024
American Academy of Neurology, MD, Mount Sinai Hospital, USF, Multiple sclerosis, AAN, Abstract (summary), University, Therapy, Patient, RMS, Publication, American Academy, Harbor

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
  • Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49 .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001

Retrieved on: 
Thursday, March 7, 2024
Annual general meeting, SAN, AAN, DSM-IV codes, Therapy, CO, American Academy

SAN FRANCISCO, March 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE), will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.

Key Points: 
  • SAN FRANCISCO, March 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE), will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.